US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

1.15

+0.04003.60%

Post-market: 1.13-0.0200-1.74%19:57 EST

Volume:1.32M

Turnover:1.45M

Market Cap:69.83M

PE:-1.74

High:1.20

Open:1.17

Low:1.02

Close:1.11

52wk High:4.44

52wk Low:0.4100

Shares:60.72M

Float Shares:54.29M

Volume Ratio:0.78

T/O Rate:2.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6627

EPS(LYR):-1.2136

ROE:-418.06%

ROA:-60.16%

PB:4.23

PE(LYR):-0.95

Loading ...

Overview Company News Filings

Tuhura Biosciences Files IND for TBS-2025 in Blood Cancer Treatment

Tuhura Biosciences Inc - Plans Phase 2 Study for Mutnpm1 R/R Aml in Q2 2026, Preliminary Stage 1 Results in Q3 2026

THOMSON REUTERS

Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers

THOMSON REUTERS

TuHURA Biosciences to Present at Oppenheimer Healthcare Life Sciences Conference

TuHURA Biosciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

FDA Grants Orphan Drug Designation to TuHURA Biosciences' IFx-2.0 for Cutaneous Melanoma

Tuhura Biosciences Received FDA Orphan Drug Designation for Ifx-2.0 for the Treatment of Stage Iib to Stage Iv Cutaneous Melanoma

THOMSON REUTERS

Nasdaq Warns Tuhura Biosciences Over Minimum Bid Price Compliance

Tuhura Biosciences Unveils Cancer Immunotherapy Advances Targeting Resistance with Three Novel Technologies

TuHURA Biosciences Price Target Cut to $10.00/Share From $12.00 by HC Wainwright & Co.

TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright

Tuhura Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $10 From $12

THOMSON REUTERS

BRIEF-Tuhura Biosciences Releases Kintara CVR After Safety Milestone

TuHURA Biosciences Reports REM-001 Meets Safety Endpoint in Metastatic Breast Cancer Trial

Tuhura Biosciences Announces Its Release of Kintara's Contingent Value Right (CVR) as Kintara's Rem-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

THOMSON REUTERS

Tuhura Biosciences Provides Corporate Update Following Recent Financing

THOMSON REUTERS

Tuhura Biosciences Shares Fall 38.5% After $15.6 Million Direct Stock Deal

THOMSON REUTERS

BUZZ-TuHURA Biosciences plunges after $15.6 million direct stock deal

Tuhura Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

THOMSON REUTERS

TuHURA Biosciences Unveils Delta Opioid Receptor Inhibitor to Overcome Cancer Immunotherapy Resistance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HURA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":1.15,"timestamp":1771621200000,"preClose":1.11,"halted":0,"volume":1317306,"hourTrading":{"tag":"盘后","latestPrice":1.13,"preClose":1.15,"latestTime":"19:57 EST","volume":3416,"amount":3865.4786,"timestamp":1771635428061,"change":-0.02,"changeRate":-0.017391,"amplitude":0.026087},"delay":0,"changeRate":0.03603603603603586,"floatShares":54286373,"shares":60720508,"eps":-0.662671,"marketStatus":"Closed","change":0.04,"latestTime":"02-20 16:00:00 EST","open":1.17,"high":1.2008,"low":1.02,"amount":1448120.1502158,"amplitude":0.162883,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.662671,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.11,"preHourTrading":{"tag":"盘前","latestPrice":1.1897,"preClose":1.11,"latestTime":"09:25 EST","volume":8263,"amount":9520.4294617,"timestamp":1771597553708,"change":0.0797,"changeRate":0.071802,"amplitude":0.071802},"postHourTrading":{"tag":"盘后","latestPrice":1.13,"preClose":1.15,"latestTime":"19:57 EST","volume":3416,"amount":3865.4786,"timestamp":1771635428061,"change":-0.02,"changeRate":-0.017391,"amplitude":0.026087},"volumeRatio":0.783205},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":54286373,"roa":"-60.16%","roe":"-418.06%","lyrEps":-1.213628,"volumeRatio":0.783205,"shares":60720508,"dividePrice":0,"high":1.2008,"amplitude":0.162883,"preClose":1.11,"low":1.02,"week52Low":0.41,"pbRate":"4.23","week52High":4.44,"institutionHeld":0,"latestPrice":1.15,"eps":-0.662671,"divideRate":0,"volume":1317306,"delay":0,"ttmEps":-0.662671,"open":1.17,"prevYearClose":0.7567,"prevWeekClose":1.33,"prevMonthClose":0.5351,"prevQuarterClose":0.7567,"fiveDayClose":1.39,"twentyDayClose":0.6793,"sixtyDayClose":1.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"HURA","fiscalQuarterEnding":"2025/09","expectedEps":-0.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-14","symbol":"HURA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-05-15","symbol":"HURA","fiscalQuarterEnding":"2025/03","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1755234000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2026-02-19","current":-1.667494,"percent":0.871166,"low":-15.284879,"twenty":-8.356462,"median":-5.129256,"eighty":-4.019886,"high":-0.912265,"avg":-5.924466,"sd":3.016633,"marketCap":68310571},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109},{"date":"2025-07-03","current":-4.911411,"twenty":-10.238281,"median":-7.856432,"eighty":-5.456208,"marketCap":115440443},{"date":"2025-07-11","current":-4.990628,"twenty":-10.201312,"median":-7.766145,"eighty":-5.256797,"marketCap":117302386},{"date":"2025-07-18","current":-5.010432,"twenty":-10.182292,"median":-7.688203,"eighty":-5.039996,"marketCap":117767871},{"date":"2025-07-25","current":-5.624358,"twenty":-10.127376,"median":-7.668851,"eighty":-5.052895,"marketCap":132197927},{"date":"2025-08-01","current":-4.911411,"twenty":-10.049579,"median":-7.615053,"eighty":-5.052895,"marketCap":115440443},{"date":"2025-08-08","current":-4.812391,"twenty":-9.994663,"median":-7.555364,"eighty":-5.037142,"marketCap":113113015},{"date":"2025-08-15","current":-4.975285,"twenty":-9.907714,"median":-7.528032,"eighty":-5.017728,"marketCap":138129515},{"date":"2025-08-22","current":-5.245681,"twenty":-9.861951,"median":-7.477167,"eighty":-5.037142,"marketCap":145636554},{"date":"2025-08-29","current":-5.065417,"twenty":-9.847676,"median":-7.326779,"eighty":-5.052895,"marketCap":140631862},{"date":"2025-09-05","current":-4.560678,"twenty":-9.79276,"median":-7.254296,"eighty":-5.013311,"marketCap":126618722},{"date":"2025-09-12","current":-4.668836,"twenty":-9.696332,"median":-7.110931,"eighty":-4.956091,"marketCap":129621538},{"date":"2025-09-19","current":-4.65081,"twenty":-9.618099,"median":-7.053585,"eighty":-4.911411,"marketCap":129121069},{"date":"2025-09-26","current":-4.416467,"twenty":-9.555338,"median":-6.959639,"eighty":-4.875184,"marketCap":122614968},{"date":"2025-10-03","current":-4.704889,"twenty":-9.532456,"median":-6.792598,"eighty":-4.824615,"marketCap":130622476},{"date":"2025-10-10","current":-4.65081,"twenty":-9.500422,"median":-6.659051,"eighty":-4.759515,"marketCap":129121069},{"date":"2025-10-17","current":-4.326335,"twenty":-9.445506,"median":-6.451252,"eighty":-4.704889,"marketCap":120112622},{"date":"2025-10-24","current":-4.019886,"twenty":-9.386014,"median":-6.151486,"eighty":-4.692197,"marketCap":111604644},{"date":"2025-10-31","current":-4.470546,"twenty":-9.301564,"median":-5.965405,"eighty":-4.668836,"marketCap":124116376},{"date":"2025-11-07","current":-4.416467,"twenty":-9.208999,"median":-5.850391,"eighty":-4.621968,"marketCap":122614968},{"date":"2025-11-14","current":-3.677385,"twenty":-9.18008,"median":-5.798151,"eighty":-4.596731,"marketCap":102095729},{"date":"2025-11-21","current":-2.774116,"twenty":-9.039762,"median":-5.662432,"eighty":-4.565822,"marketCap":81244064},{"date":"2025-11-28","current":-3.500461,"twenty":-8.84257,"median":-5.63426,"eighty":-4.556086,"marketCap":102516170},{"date":"2025-12-05","current":-3.465457,"twenty":-8.730961,"median":-5.593729,"eighty":-4.544729,"marketCap":101491008},{"date":"2025-12-12","current":-1.811489,"twenty":-8.705462,"median":-5.561421,"eighty":-4.506599,"marketCap":53052117},{"date":"2025-12-19","current":-1.552105,"twenty":-8.587093,"median":-5.505534,"eighty":-4.470546,"marketCap":45455669},{"date":"2025-12-26","current":-1.707387,"twenty":-8.521606,"median":-5.445058,"eighty":-4.45252,"marketCap":50003338},{"date":"2026-01-02","current":-1.568888,"twenty":-8.50549,"median":-5.407919,"eighty":-4.416467,"marketCap":45947208},{"date":"2026-01-09","current":-1.564327,"twenty":-8.469228,"median":-5.371294,"eighty":-4.409256,"marketCap":45813623},{"date":"2026-01-16","current":-1.57656,"twenty":-8.46117,"median":-5.317787,"eighty":-4.331172,"marketCap":46171874},{"date":"2026-01-23","current":-1.408413,"twenty":-8.46117,"median":-5.267885,"eighty":-4.319125,"marketCap":41247441},{"date":"2026-01-30","current":-1.163138,"twenty":-8.430269,"median":-5.249422,"eighty":-4.265631,"marketCap":34064204},{"date":"2026-02-06","current":-0.912265,"twenty":-8.395844,"median":-5.227655,"eighty":-4.145319,"marketCap":26717023},{"date":"2026-02-13","current":-2.881928,"twenty":-8.370916,"median":-5.188669,"eighty":-4.09774,"marketCap":84401506},{"date":"2026-02-19","current":-2.332496,"twenty":-8.356462,"median":-5.129256,"eighty":-4.019886,"marketCap":68310571}],"updateTime":1771614716109},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612752454","title":"Tuhura Biosciences Files IND for TBS-2025 in Blood Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612752454","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612752454?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:45","pubTimestamp":1771332332,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Files IND for TBS-2025 in Blood Cancer Treatment               TuHURA Biosciences Inc. has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL34f3K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2612764454","title":"Tuhura Biosciences Inc - Plans Phase 2 Study for Mutnpm1 R/R Aml in Q2 2026, Preliminary Stage 1 Results in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612764454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612764454?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:45","pubTimestamp":1771332300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA1DQTZ1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2612454767","title":"Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2612454767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612454767?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:45","pubTimestamp":1771332300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA1DQTZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2610926617","title":"TuHURA Biosciences to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2610926617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610926617?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:45","pubTimestamp":1770900313,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL8tHtJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2608879241","title":"TuHURA Biosciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879241?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:11","pubTimestamp":1770124260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 08:11 ET (13:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2608691418","title":"FDA Grants Orphan Drug Designation to TuHURA Biosciences' IFx-2.0 for Cutaneous Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2608691418","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608691418?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:45","pubTimestamp":1770036322,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. announced that the U.S. Food and Drug Administration  Office of Orphan Products Development has granted Orphan Drug Designation to its candidate IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. This designation provides TuHURA with benefits including seven years of market exclusivity, increased FDA engagement and assistance, tax credits for certain research, research grants, and a waiver of the New Drug Application user fee. No other beneficiary organizations were mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on February 02, 2026, and is solely responsible for the informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3l1ggn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2608869924","title":"Tuhura Biosciences Received FDA Orphan Drug Designation for Ifx-2.0 for the Treatment of Stage Iib to Stage Iv Cutaneous Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608869924?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:45","pubTimestamp":1770036300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1XY2QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2607386021","title":"Nasdaq Warns Tuhura Biosciences Over Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2607386021","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607386021?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:01","pubTimestamp":1769806881,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has received a notice from Nasdaq indicating that its common stock has traded below the $1.00 minimum bid price requirement for 35 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5550. The company has been granted a 180-day grace period, until July 28, 2026, to regain compliance. If it does not meet the requirement within this period, Tuhura may be eligible for a second 180-day extension, provided it meets other initial listing standards and notifies Nasdaq of its intention to address the deficiency, potentially including a reverse stock split. Failure to regain compliance could result in delisting from the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDLcg1Ck6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2603628365","title":"Tuhura Biosciences Unveils Cancer Immunotherapy Advances Targeting Resistance with Three Novel Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2603628365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603628365?lang=en_us&edition=fundamental","pubTime":"2026-01-15 07:19","pubTimestamp":1768432740,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has released a corporate presentation outlining its progress in developing immuno-oncology therapeutics aimed at overcoming resistance to cancer immunotherapies. The company’s lead asset, IFx-2.0, is currently in a Phase 3 front-line study for Merkel Cell Cancer, with top-line data expected in the first half of 2027. This trial is being conducted under a Special Protocol Assessment  agreement with the U.S. Food and Drug Administration. Preliminary data from a Phase 1/2 study of IFx-2.0 will be presented at ASCO 2026. Tuhura’s pipeline includes a second asset, TBS-2025, targeting VISTA in NPM1-mutated acute myeloid leukemia , which will enter Phase 2 trials in early 2026, with data anticipated later that year. A third program involving bi-specific antibody-drug conjugates  is expected to reach in vivo proof-of-concept in 2026, opening potential partnering opportunities. The company reports a cash position that supports advancement through multiple key milestones.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL758LqY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2602378399","title":"TuHURA Biosciences Price Target Cut to $10.00/Share From $12.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2602378399","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602378399?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:56","pubTimestamp":1767959760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 06:56 ET (11:56 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2602327025","title":"TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602327025?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:16","pubTimestamp":1767957361,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns lowered the firm’s price target on TuHURA Biosciences (HURA) to $10 from $12 and keeps a Buy rating on the sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-10-from-12-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-10-from-12-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2602327142","title":"Tuhura Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $10 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327142","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602327142?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:14","pubTimestamp":1767957292,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nAZN4RTBRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2591644323","title":"BRIEF-Tuhura Biosciences Releases Kintara CVR After Safety Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644323","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644323?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:59","pubTimestamp":1765807157,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Releases Kintara CVR After Safety MilestoneDec 15 (Reuters) - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES ANNOUNCES ITS RELEASE OF KINTARA'S CONTINGENT VALUE RIGHT (CVR) ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA4TN5HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2591649887","title":"TuHURA Biosciences Reports REM-001 Meets Safety Endpoint in Metastatic Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649887?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:50","pubTimestamp":1765803029,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc. announced that the REM-001 clinical trial in ten patients with metastatic cutaneous breast cancer met its primary safety endpoint and demonstrated signs of clinical efficacy following eight weeks of follow-up. As a result, a milestone was achieved, triggering the release of 1,539,958 shares of TuHURA common stock to legacy Kintara Therapeutics stockholders, as specified in the Contingent Value Rights Agreement. The shares are expected to be distributed to CVR holders within the next ten business days. Results from the REM-001 study have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLkVGXf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2591646059","title":"Tuhura Biosciences Announces Its Release of Kintara's Contingent Value Right (CVR) as Kintara's Rem-001 Meets Primary Safety Endpoint Achieving Contractual Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2591646059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591646059?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:50","pubTimestamp":1765803000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA4TN5HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2590132235","title":"Tuhura Biosciences Provides Corporate Update Following Recent Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590132235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590132235?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA5SCYCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2590340023","title":"Tuhura Biosciences Shares Fall 38.5% After $15.6 Million Direct Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2590340023","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590340023?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:02","pubTimestamp":1765296143,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2590285340","title":"BUZZ-TuHURA Biosciences plunges after $15.6 million direct stock deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2590285340","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590285340?lang=en_us&edition=fundamental","pubTime":"2025-12-09 23:56","pubTimestamp":1765295774,"startTime":"0","endTime":"0","summary":"BUZZ-TuHURA Biosciences plunges after $15.6 million direct stock deal** Drug developer TuHURA Biosciences' HURA.O shares plunge 36.9% to $1.25** HURA enters agreement for sale of ~9.5 million shares, Series A warrants, and Series B warrants in a registered direct offering at a purchase price of $1.65 apiece for gross proceeds of $15.6 million** H.C. Wainwright is the exclusive lead placement agent for offering** Closing of the offering is expected to occur in three tranches** Proceeds from the offering will be used for working capital and general purposes** All three analysts covering the stock rate it \"buy\"; median PT $9.13 - data compiled by LSEG** As of last close, HURA stock down 51.6% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3CF3QU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2590099342","title":"Tuhura Biosciences, Inc. Announces $15.6 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590099342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590099342?lang=en_us&edition=fundamental","pubTime":"2025-12-09 22:50","pubTimestamp":1765291801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA92V3GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2589635845","title":"TuHURA Biosciences Unveils Delta Opioid Receptor Inhibitor to Overcome Cancer Immunotherapy Resistance","url":"https://stock-news.laohu8.com/highlight/detail?id=2589635845","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589635845?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:50","pubTimestamp":1765198220,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. announced the presentation of new research on the Delta Opioid Receptor  as a novel target for overcoming acquired resistance to cancer immunotherapy. The results were presented at the 67th American Society of Hematology  Annual Meeting and Exposition. The company reported that DOR is expressed on tumor-associated myeloid-derived suppressor cells  and tumor-associated macrophages , and that inhibition of DOR reduces the immunosuppressive capabilities of these cells. TuHURA also highlighted the development of a library of selective and potent DOR antagonists and plans to advance a lead antibody drug conjugate  candidate consisting of a DOR inhibitor linked to a VISTA inhibiting antibody. The company stated that these ADCs have the potential to modulate the tumor microenvironment and support immune recognition of leukemic cells.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1MXxZf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}